Advances in nano-delivery systems for doxorubicin: an updated insight

• Published in: Journal of drug targeting Vol. 26; no. 4; pp. 296 - 310
• Main Authors: Kanwal, Ummarah, Irfan Bukhari, Nadeem, Ovais, Muhammad, Abass, Nasir, Hussain, Khalid, Raza, Abida
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 21.04.2018
• Subjects: Animals; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - pharmacokinetics; Antibiotics, Antineoplastic - toxicity; cardiotoxicity; Cardiotoxicity - etiology; Cardiotoxicity - prevention & control; Doxil; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Doxorubicin - pharmacokinetics; Drug Delivery Systems; Half-Life; Humans; Liposomes; Medication Adherence; Myocet; nano delivery systems; Nanoparticles; Neoplasms - drug therapy; Neoplasms - pathology; Doxil; cardiotoxicity; Doxorubicin; Myocet; nano delivery systems

Doxorubicin (DOX) is the most effective chemotherapeutic drug developed against broad range of cancers such as solid tumours, transplantable leukemias and lymphomas. Conventional DOX-induced cardiotoxicity has limited its use. FDA approved drugs i.e. non-pegylated liposomal (Myocet ® ) and pegylated...